Agilent Expands Precision Oncology, Digital Pathology at USCAP 2026
Event summary
- Agilent will showcase advances in precision oncology and digital pathology at USCAP 2026, March 21-26 in San Antonio, Texas.
- New PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) expands biomarker testing capabilities.
- Dako Omnis family of instruments highlighted as a foundation for scalable, automation-ready pathology laboratories.
- Collaborations with Hamamatsu, Proscia, PathAI, and Visiopharm to demonstrate interoperable digital pathology solutions.
The big picture
Agilent’s focus on precision oncology and digital pathology aligns with the broader industry shift towards data-driven, automated diagnostic solutions. The company’s strategy to integrate staining, imaging, and data management reflects a push towards more efficient and reproducible pathology workflows. With collaborations reinforcing its ecosystem, Agilent aims to solidify its role as a trusted provider of integrated pathology solutions.
What we're watching
- Market Adoption
- The pace at which laboratories adopt Agilent’s digital pathology workflows will determine the scalability of its solutions.
- Competitive Positioning
- Whether Agilent can sustain its leadership in precision oncology amid increasing competition.
- Regulatory Landscape
- How evolving regulatory requirements for biomarker testing will impact Agilent’s product portfolio.
Related topics